Eptinezumab treatment for chronic migraine was associated with significant reduction in migraine-related burden on work, home, and social functioning.
Combined stimulation of the occipital and trigeminal nerves using a non-invasive stimulation device was found to be effective for the acute treatment of migraine.
Atogepant was found to be safe and effective for reducing the mean monthly migraine days.
A single dose of oral rimegepant may provide safe, fast, and sustained relief from migraine.
Lacosamide, an anti-epileptic drug that inhibits phosphorylation of collapsing response mediator protein 2 and blocks the release of calcitonin gene-related peptide in the trigeminal system, may be effective in the treatment of chronic migraine.
Ubrogepant has demonstrated efficacy in treating acute migraine among individuals for whom triptan has not been effective.
OnabotulinumtoxinA has demonstrated efficacy, safety, and tolerability in treating chronic migraine.
Individuals with an implantable programmable cerebrospinal fluid shunt are at risk for unintended changes to valve settings through exposure to magnetic fields present in implantable medical devices.
Study utilizing metabolic markers and magnetic resonance imaging finds cerebral degeneration is more pronounced in the motor cortex compared with the prefrontal cortex in patients with ALS.
Researchers pooled data from 2 randomized, double-blind, placebo-controlled trials and found that noninvasive VNS is effective in aborting attacks in episodic cluster headache.